Home › Research › Treatments
Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab
Neuroradiologie Scan, 2026-04-01
Topic: Amyloid, tau and blood-test diagnosis
Im Zuge der Alzheimerkrankheit lagern sich Beta-Amyloid-Plaques im Gehirn ab. Der monoklonale Antikörper Lecanemab beugt diesen Plaques vor, indem er lösliche Beta-Amyloid-Fibrillen bindet und deren Clearance fördert. Allerdings begünstigen solche Antiamyloidtherapien ARIA (amyloid-related imaging abnormalities) in der MRT, die ein regelmäßiges Monitoring notwendig machen. US-Forschende prüften nun, welche Bildgebungsbiomarker ARIA vorhersagen. Fazit Vor einer Antiamyloidtherapie bei Alzheimerkrankheit muss die zerebrovaskuläre Gesundheit beurteilt werden, so die Forschenden: Eine starke DWMH-Belastung korreliert offenbar mit einem signifikant höheren ARIA-Risiko. Sie hoffen, dass dieser Bildgebungsmarker zukünftig bei der Risikostratifizierung sowie bei Therapieentscheidungen helfen kann. Größere Studien müssen nun weitere vaskuläre Biomarker identifizieren. Perspektivisch hoffen sie so auf differenziertere Prädiktionsmodelle. Publication History Article published online: 10 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab. (2026). Neuroradiologie Scan. https://doi.org/10.1055/a-2788-0873
Vancouver
Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab. Neuroradiologie Scan. 2026. doi:10.1055/a-2788-0873.
BibTeX
@article{study2026-b85e6325,
title = {{Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab}},
journal = {Neuroradiologie Scan},
year = {2026},
doi = {10.1055/a-2788-0873},
url = {https://doi.org/10.1055/a-2788-0873}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Sie hoffen, dass dieser Bildgebungsmarker zukünftig bei der Risikostratifizierung sowie bei Therapieentscheidungen helfen kann.
- Größere Studien müssen nun weitere vaskuläre Biomarker identifizieren.
- Perspektivisch hoffen sie so auf differenziertere Prädiktionsmodelle.
- Publication History Article published online: 10 April 2026 © 2026.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
Lecanemab binds soluble beta-amyloid fibrils and promotes their clearance, but anti-amyloid therapies can cause ARIA on MRI, making regular monitoring necessary. A strong DWMH burden appears to correlate with a significantly higher ARIA risk, and larger studies are needed to identify further vascular biomarkers.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 24 of the 93 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuroradiologie Scan) |
| Journal's citation record | 0 / 4 | Neuroradiologie Scan: journal h-index 4 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 24 of the 93 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.